Advances in Cancer Immunotherapy and Stem Cell Research

EnglishTürkçe

CHAPTER


DOI :10.26650/B/LS17LS30.2025.038.003   IUP :10.26650/B/LS17LS30.2025.038.003    Full Text (PDF)

Chimeric Antigen Receptor (Car) T Cell Therapy

Hikmet Gülşah Tanyıldız, Zeynep Karakaş

Cancer is one of the most common causes of death in children. More than 300.000 children are diagnosed with cancer all over the world in a year. Chemotherapy, radiotherapy, surgery, smart drugs, stem cell transplants and immunotherapies are among the standard treatment options. When a tumor is confined, tiny, and non-metastatic, surgery is beneficial. If the resection is insufficient, there is a chance that the cancer will return. Despite its efficiency, radiation and chemotherapy damage healthy tissues and can have serious side effects. As a result, new therapeutic modalities, like immunotherapy using CAR-T cells, are being used. Although it has shown great success in treating pediatric hematological malignancies, there is still scant information on solid tumors. Lately, Chimeric Antigen Receptor (CAR) T cell therapy has come to the agenda as a one of confidence and effective alternative treatment in cancer. Instead of classical treatment CAR-T has been promising more effective and a durable treatment in some of childhood cancers. CAR-T cell and immunotherapy are seen as the ”fifth basic pole” of cancer treatment in the scientific community


Keywords: CAR-T cell, childhood cancers, treatment

References

  • 1. Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019;34:45-55. google scholar
  • 2. Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019:7;15(12):2548-60. google scholar
  • 3. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021:6;11(4):69. google scholar
  • 4. Celichowski P, Turi M, Charvatova S, Radhakrishnan D, Feizi N, Chyra Z, et al. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility. J Transl Med. 2023;15:21(1):197. google scholar
  • 5. Sarwish R, Christopher S.H, Renier J.B. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature Reviews Clinical Oncolcogy. 2019;17(3):1-21. google scholar
  • 6. Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359-71. google scholar
  • 7. Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;12:10:2664. google scholar
  • 8. Neelapu S.S, Locke F.L, Bartlett N.L, Lekakis L.J, Reagan P.M, Miklos D.B, et al. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv 2021;5(20):4149-55. google scholar
  • 9. Si W, Li C. Wei P. Synthetic immunology: T-cell engineering and adoptive immunotherapy. Synth Syst Biotechnol. 2018;3(3):179-85. google scholar
  • 10. Titov A, Valiullina A, Zmievskaya E, Zaikova E, Petukhov A, Miftakhova R. et al. Advancing CAR T-cell therapy for solid tumors: lessons learned from lymphoma treatment. Cancers. 2020;(12):125:1-22. google scholar
  • 11. Schuster S.J, Bishop M.R, Tam C.S, Waller E.K, Borchmann P, McGuirk J.P. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45-56. google scholar
  • 12. Mardiana S, Gill S. CAR T cells for acute myeloid leukemia: state of the art and future directions. Front Oncol. 2020;10:697. google scholar
  • 13. Ho C, Ruella M, Levine B.L, Svoboda J. Adoptive T-cell therapy for Hodgkin lymphoma. Bllod Adv. 2021;5(20);4291-302. google scholar
  • 14. Richards RM, Elena Sotillo E, Majzner RG. CAR T cell therapy for neuroblastoma. Front Immunol. 2018;9:2380. google scholar
  • 15. Stokes CL, Stokes WA, Kalapurakal JA, Paulino AC, Cost NG, Cost CR, et al. Timing of radiation therapy in pediatric wilms tumor: A report from the national cancer database. Int J Radiat Oncol Biol Psys. 2018;101:453-61. google scholar
  • 16. Capurro, MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65:6245-54. google scholar
  • 17. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7-33. google scholar
  • 18. Park JA, Cheung NV. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma. J Hematol Oncol. 2020;13:172. google scholar
  • 19. Huang, G, Yu L, Cooper LJ, Hollomon M, Huls H, Kleinerman ES. Genetically modified T cells targeting interleukin-llreceptor a-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res. 20l2;72:27l-8l. google scholar
  • 20. Yuan D, Liu B, Liu K, Zhu G, Dai Z, Xie Y. Overexpression of fibroblast activation protein and its clinical implications in patients with osteosarcoma. J Surg Oncol. 2013;108:157-62. google scholar
  • 21. Shah MH, Lorigan, P, O’Brien ME, Fossella FV, Moore KN, Bhatia S, et al. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. Investig. New Drugs. 2016;34:290-9. google scholar
  • 22. Howley S, Stack D, Morris T, McDermott M, Capra M, Betts D, O’Sullivan MJ. Ectomesenchymoma with t(1;12)(p32;p13) evolving from embryonal rhabdomyosarcoma shows no rearrangement of ETV6. Hum Pathol. 2012;43:299-302. google scholar
  • 23. Bozzi F, Collini P, Aiello A, Barzano E, Gambirasio F, Podda M, et al. R. Flow cytometric phenotype of rhabdomyosarcoma bone marrow metastatic cells and its implication in differential diagnosis with neuroblastoma. Anticancer Res. 2008;28:1565-9. google scholar
  • 24. Manrique, M.; Akinbolue, D.; Madigan, W.P.; Bregman, J. Update on the treatment of retinoblastoma. Neo Reviewers. 2021;22:e423-37. google scholar
  • 25. Andersch L, Radke J, Klaus A, Schwiebert S, Winkler A, Schumann E, et al. CD171-and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. BMC Cancer. 2019;19:895. google scholar
  • 26. Wang K, Chen Y, Ahn S, Zheng M, Landoni E, Dotti G, et al. GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision. Nat Cancer. 2020;1(10):990-7. google scholar
  • 27. LinZ,WuZ,LuoW. A novel treatment for Ewing’s sarcoma: chimeric antigen receptor-T cell therapy. Front Immunol. 2021;12:707211. google scholar
  • 28. Hou B, Tang Y, Li W, Zeng Q, Chang D. Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: a meta-analysis. Dis Markers. 2019:2019:3425291. google scholar
  • 29. Wang SS, Bandopadhayay P, Jenkins MR. Towards immunotherapy for pediatric brain tumors. Trends Immunol. 2019;40(8):748-61. google scholar


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.